Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cocarboxylase→

Cocarboxylase Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
154-87-0
Molecular formula
C12H19ClN4O7P2S
Molecular weight
460.77 g/mol
Drug class
Thiamine pyrophosphate (TPP)active coenzyme form of vitamin B1
Mechanism of action
Serves as an essential cofactor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, branched-chain alpha-ketoacid dehydrogenase and transketolase, supporting carbohydrate and energy metabolism.
Indications / reported uses
  • Replacement of thiamine coenzyme activity in selected deficiency or metabolic conditions where parenteral cocarboxylase products are authorised; routine use beyond established thiamine deficiency requires product-specific evidence

Sources: NIH Office of Dietary Supplements — Thiamin fact sheet · NLM MeSH — Thiamine pyrophosphate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cocarboxylase Environmental Risk Assessment (ERA) (the Cocarboxylase ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.